MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Heron Therapeutics Inc

Closed

SectorHealthcare

1.92 -4.95

Overview

Share price change

24h

Current

Min

1.92

Max

1.96

Key metrics

By Trading Economics

Income

-1M

2.6M

Sales

-1.9M

39M

Profit margin

6.773

Employees

122

EBITDA

-5M

3.7M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+212.5% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-28M

323M

Previous open

6.87

Previous close

1.92

News Sentiment

By Acuity

25%

75%

54 / 376 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Heron Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

18 Jul 2025, 21:01 UTC

Earnings

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 Jul 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

18 Jul 2025, 20:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

18 Jul 2025, 20:50 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

18 Jul 2025, 20:46 UTC

Earnings

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 Jul 2025, 20:39 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 Jul 2025, 20:36 UTC

Earnings

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 Jul 2025, 20:16 UTC

Acquisitions, Mergers, Takeovers

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 Jul 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 Jul 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 Jul 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 Jul 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 Jul 2025, 18:24 UTC

Earnings

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 Jul 2025, 18:19 UTC

Earnings

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 Jul 2025, 18:11 UTC

Acquisitions, Mergers, Takeovers

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 Jul 2025, 18:11 UTC

Earnings

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 Jul 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 Jul 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 Jul 2025, 16:28 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 Jul 2025, 16:22 UTC

Earnings

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 Jul 2025, 16:20 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

18 Jul 2025, 16:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

18 Jul 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

18 Jul 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

18 Jul 2025, 16:20 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

18 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 Jul 2025, 16:04 UTC

Earnings

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 Jul 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 Jul 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 Jul 2025, 15:47 UTC

Market Talk
Earnings

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Peer Comparison

Price change

Heron Therapeutics Inc Forecast

Price Target

By TipRanks

212.5% upside

12 Months Forecast

Average 6.25 USD  212.5%

High 9 USD

Low 4 USD

Based on 4 Wall Street analysts offering 12 month price targets forHeron Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

2.0001 / 2.42Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

54 / 376 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.